Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

Summary

The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.

Timeline

Start

2024-12-09

Primary completion

2025-09-30

Completion

2026-03-07

Outcome

Met primary endpoint

release “announced today positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo in 493 people living with overweight and obesity” gene.com ↗

Drugs

Indications